UK – Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

akeda’s Exkivity (mobocertinib) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for the treatment of epidermal growth factor receptor (EGFR) Exon 20 insertion mutation-positive (Exon20ins+) advanced non-small cell lung cancer (NSCLC), who have already received platinum-based chemotherapy.

Par
RIS.WORLD
-
NICE ‘OK’ for Lynparza

The treatment was licensed through by Project Orbis, an international programme to review and approve promising cancer drugs helping patients access treatments faster.

NICE’s decision was supported by positive results from a phase 1/2 trial of Exkivity evaluating the safety and efficacy of oral Exkivity in patients with NSCLC.

At the November 2021 data cut off for the study, a pooled analysis of platinum pre-treated patients with EGFR Exon20 ins+ mNSCLC receiving Exkivity at a daily dose of 160mg demonstrated a confirmed objective response rate of 28%, a median duration of response of 15.8 months, a median progression free survival of 7.3 months and a median overall survival of 20 months…

ARTICLES CONNEXESPLUS DE L'AUTEUR